New immune therapy combo tested for common blood cancer
NCT ID NCT05783609
Summary
This study is testing a new two-drug combination for adults who have not yet received treatment for follicular lymphoma, a type of slow-growing blood cancer. The goal is to see if adding a newer drug (epcoritamab) to a standard one (rituximab) is safe and more effective at controlling the cancer. About 100 participants will receive the treatment for about 9-10 months and be followed for up to 10 years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
Contact
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Ohio State University Wexner Medical Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Email: •••••@•••••
-
University of Rochester Medical Center
RECRUITINGRochester, New York, 14642, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.